Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06581744
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-27
Brief Title:
Non Invasive Imaging Methods for Detecting PAa Clinical PET Study of 18F-Pentixather
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Non Invasive Imaging Methods for Detecting Primary Aldosteronism a Clinical Positron EmissionTomography PET Study of 18F-Pentixather
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Primary aldosteronism PA is the most common endocrine cause of hypertension 68Ga-pentixafor PETCT possesses a relatively high sensitivity and specificity for Aldosterone producing adenoma APA detection However 68Ga is usually eluted from a 68Ge-68Ga generator only a small amount of isotopes can be achieved once time 18FAlF-chelation is a promising strategy that would solve these issues 18F labeled Pentixafor-Based Imaging Agent18FAlF-NOTA-Pentixather has been reported by Andreas Poschenrieder 18FAlF-NOTA-Pentixather displayed high and CXCR4-specific in vivo uptake in Daudi xenografts 13908 injected dose per gram IDg at 1 hour post injectionpi But to date 18F-Pentixather has not been studied in humans In this program the investigators will estimate the radiation dosimetry of 18FAlF-NOTA-Pentixather evaluate the sensitivity and specificity of the 18FAlF-NOTA-Pentixather as a probe for APA
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None